Lupin receives tentative USFDA approval for Sitagliptin Tablets
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Lacosamide is indicated to treat partial-onset seizures
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
10+ emerging markets, Japan & ANZ transition in final phase
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
The product will be manufactured at Lupin's Pithampur facility in India
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Subscribe To Our Newsletter & Stay Updated